Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma During Targeted Therapy

FGFR2 fusions occur in 10% to 15% of patients with intrahepatic cholangiocarcinoma (iCCA), potentially benefiting from FGFR inhibitors (FGFRi). We aimed to assess the feasibility of detecting FGFR2 fusions in plasma and explore plasma biomarkers for managing FGFRi treatment. We conducted a retrospec...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical cancer research Vol. 30; no. 19; p. 4491
Main Authors:	González-Medina, Alberto, Vila-Casadesús, Maria, Gomez-Rey, Marina, Fabregat-Franco, Carles, Sierra, Alexandre, Tian, Tian V, Castet, Florian, Castillo, Gloria, Matito, Judit, Martinez, Paola, Miquel, Josep M, Nuciforo, Paolo, Pérez-López, Raquel, Macarulla, Teresa, Vivancos, Ana
Format:	Journal Article
Language:	English
Published:	United States 01.10.2024
Subjects:	Adult Aged Bile Duct Neoplasms - blood Bile Duct Neoplasms - drug therapy Bile Duct Neoplasms - genetics Bile Duct Neoplasms - mortality Bile Duct Neoplasms - pathology Biomarkers, Tumor - blood Biomarkers, Tumor - genetics Cholangiocarcinoma - blood Cholangiocarcinoma - diagnosis Cholangiocarcinoma - drug therapy Cholangiocarcinoma - genetics Cholangiocarcinoma - pathology Circulating Tumor DNA - blood Circulating Tumor DNA - genetics Female High-Throughput Nucleotide Sequencing - methods Humans Liquid Biopsy - methods Male Middle Aged Molecular Targeted Therapy - methods Oncogene Proteins, Fusion - genetics Prognosis Protein Kinase Inhibitors - therapeutic use Receptor, Fibroblast Growth Factor, Type 2 - genetics Retrospective Studies
ISSN:	1557-3265, 1557-3265
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!